E-mail this story
FDA panel backs a new sleep drug
An advisory panel to the Food & Drug Administration has recommended approval of a new sleep drug that targets the brain's wakefulness centers, but suggested the agency should consider a dose of the drug, called suvorexant, lower than that proposed by the medication's maker, Merck. In doing so, members of the FDA's advisory committee on peripheral and central nervous system drugs appeared to agree with concerns raised by FDA staff scientists that, at higher doses, the sleep medication may cause dangerous next-day drowsiness in some patients.
By Melissa Healy
May 22, 2013